b-rayZ, a Swiss innovator in AI-powered medical imaging solutions, proudly announces the receipt of the CE mark for the groundbreaking DANAI technology

January 22, 2024 — b-rayZ, a Swiss innovator in AI-powered medical imaging solutions, proudly announces the receipt of the CE mark for the groundbreaking DANAI technology. Seamlessly integrated into the comprehensive breast diagnostic suites, b-box plus, DANAI empowers breast cancer detection, density assessment and quality-controlled breast positioning. DANAI marks a significant milestone in radiology, introducing a pioneering Custom AI framework designed to dynamically adapt to the unique needs of breast imaging institutions and its professional staff. Representing a paradigm shift in AI technology, it leverages adaptability to seamlessly integrate within diverse clinical environments. This adaptable framework allows calibration to the distinct requirements of each imaging unit, thereby enhancing diagnostic accuracy and streamlining operational efficiencies. 

Prof. Dr. Cristina Rossi, CEO of b-rayZ, expressed her excitement over this accomplishment, stating, “The CE mark for DANAI is a tribute to our commitment to innovation and excellence in breast imaging. With this achievement, b-rayZ elevates itself in the medical industry as the first company to cover the entire mammography workflow, closing the last gap in the adoption of AI in each and every setting with Custom AI capabilities. This innovation revolutionizes the diagnostic landscape through our commitment to the highest quality breast cancer diagnostics.“ 

The DANAI technology is set to launch in the forthcoming weeks, coinciding with a grand showcase at the European Congress of Radiology (ECR) 2024 in Vienna. The event will offer an exclusive opportunity for industry professionals to experience firsthand the transformative capabilities and adaptability of DANAI within diverse clinical settings. 

b-rayZ is set to redefine AI capabilities with DANAI, offering a revolutionary custom AI framework that ensures optimal adaptability, safety, precision, and efficiency in diagnostic processes. The launch marks a pivotal moment in advancing the field of medical imaging, setting new standards for excellence and innovation. 

For more information: https://b-rayz.com


Related Content

News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
Feature | Cardiac Imaging | Kyle Hardner

Advances in coronary CT angiography (CCTA) have reached the point where image quality and AI capabilities are creating ...

Time February 06, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Lung Imaging

Feb. 3, 2026 — RevealDx, a leader in the characterization of lung nodules, recently announced FDA clearance of RevealAI ...

Time February 04, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
Subscribe Now